Qiuying Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiuying Han has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Tao Zhou
Nanhu Laboratory, National Center of Biomedical Analysis, Beijing, China
44 shared publications - Ailing Li
Nanhu Laboratory, National Center of Biomedical Analysis, Beijing, China
43 shared publications - Huiyan Li
Nanhu Laboratory, State Key Laboratory of Biomedical Analysis (SKLBA, also known as National Center of Biomedical Analysis), Beijing, China
43 shared publications - Weina Zhang
State Key Laboratory of Biomedical Analysis (SKLBA) (formerly known as National Center of Biomedical Analysis) 1 Nanhu Laboratory Beijing
43 shared publications - Xuemin Zhang
National Center of Biomedical Analysis
43 shared publications - Bohan Li
Department of Neurosurgery, Beijing Fengtai Hospital, Beijing, China. 5
42 shared publications
Latest Publications
- 27 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Vanin-pantethine metabolic axis shapes dendritic cell function and affects inflammatory disorder progression
Aberrant activation of dendritic cells (DCs) is intricately associated with inflammatory diseases, rendering DCs an appealing therapeutic target. Metabolites are emerging as crucial regulators of DCs, yet therapeutic strategies targeting DC metabolism for inflammatory diseases remain underexplored. Our study identifies the Vanin-pantethine-cholesterol axis as a key metabolic pathway that governs DC activation—a classical APC function. We found that Vanin is upregulated in activated DCs from autoimmune patients and mice; DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice. Mechanistically, Vanin hydrolyzes pantethine, leading to cholesterol and lipid raft accumulation on the cell membrane and promoting DC hyperactivation. Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation. Notably, pantethine or RR6 treatment impairs activation of patient-derived DCs, and our investigator-initiated trial shows that pantethine combination therapy relieves clinical symptoms in psoriasis patients. Collectively, these findings establish the Vanin-pantethine-cholesterol axis as a key modulator of APC function, offering a promising metabolic approach for inflammatory diseases.
- 27 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Vanin-pantethine metabolic axis shapes dendritic cell function and affects inflammatory disorder progression
Aberrant activation of dendritic cells (DCs) is intricately associated with inflammatory diseases, rendering DCs an appealing therapeutic target. Metabolites are emerging as crucial regulators of DCs, yet therapeutic strategies targeting DC metabolism for inflammatory diseases remain underexplored. Our study identifies the Vanin-pantethine-cholesterol axis as a key metabolic pathway that governs DC activation—a classical APC function. We found that Vanin is upregulated in activated DCs from autoimmune patients and mice; DC-specific Vanin deficiency significantly alleviates psoriasiform inflammation in mice. Mechanistically, Vanin hydrolyzes pantethine, leading to cholesterol and lipid raft accumulation on the cell membrane and promoting DC hyperactivation. Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation. Notably, pantethine or RR6 treatment impairs activation of patient-derived DCs, and our investigator-initiated trial shows that pantethine combination therapy relieves clinical symptoms in psoriasis patients. Collectively, these findings establish the Vanin-pantethine-cholesterol axis as a key modulator of APC function, offering a promising metabolic approach for inflammatory diseases.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S6 shows the sequences of shRNAs used in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S6 shows the sequences of shRNAs used in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S3 shows UCSC-predicted transcription factors that bind to CKB promoters.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S3 shows UCSC-predicted transcription factors that bind to CKB promoters.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S1 shows PCr IHC staining score in human glioma microarray.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S1 shows PCr IHC staining score in human glioma microarray.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S4 shows PCr and BRD2 IHC staining scores in the serial sections of human glioma microarrays.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S4 shows PCr and BRD2 IHC staining scores in the serial sections of human glioma microarrays.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S8 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Figures S1 shows that GSCs produce high levels of phosphocreatine through upregulating CKB. Supplementary Figures S2 shows that ZEB1 promotes CKB transcription in GSCs. Supplementary Figures S3 shows that knockdown of CKB impedes GBM growth. Supplementary Figures S4 shows that disruption of phosphocreatine production impedes GBM growth. Supplementary Figures S5 shows that cCr treatment shows no side effect on mice. Supplementary Figures S6 shows that phosphocreatine binds to BRD2 and inhibits its ubiquitin mediated proteasomal degradation. Supplementary Figures S7 shows that phosphocreatine promotes chromosome segregation and GSC proliferation through BRD2 mediated transcription. Supplementary Figures S8 shows that disruption of phosphocreatine biosynthesis by cCr improves JQ1 therapeutic efficacy in GBM.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S8 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Figures S1 shows that GSCs produce high levels of phosphocreatine through upregulating CKB. Supplementary Figures S2 shows that ZEB1 promotes CKB transcription in GSCs. Supplementary Figures S3 shows that knockdown of CKB impedes GBM growth. Supplementary Figures S4 shows that disruption of phosphocreatine production impedes GBM growth. Supplementary Figures S5 shows that cCr treatment shows no side effect on mice. Supplementary Figures S6 shows that phosphocreatine binds to BRD2 and inhibits its ubiquitin mediated proteasomal degradation. Supplementary Figures S7 shows that phosphocreatine promotes chromosome segregation and GSC proliferation through BRD2 mediated transcription. Supplementary Figures S8 shows that disruption of phosphocreatine biosynthesis by cCr improves JQ1 therapeutic efficacy in GBM.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S5 shows the detailed genetic mutations of four GBM cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S5 shows the detailed genetic mutations of four GBM cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S7 shows the primer sequences used for Real-Time PCR.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S7 shows the primer sequences used for Real-Time PCR.
- Open Access
- 23 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.
- 23 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2
Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.